Cargando…

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier

Idiopathic pulmonary fibrosis is a progressive disease of unknown etiology characterized by a dysregulated wound healing response that leads to fatal accumulation of fibroblasts and extracellular matrix (ECM) in the lung, which compromises tissue architecture and lung function capacity. Injury to ty...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camelo, Ana, Dunmore, Rebecca, Sleeman, Matthew A., Clarke, Deborah L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887273/ https://www.ncbi.nlm.nih.gov/pubmed/24454287 http://dx.doi.org/10.3389/fphar.2013.00173

Ejemplares similares

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
por: Mei, Qianru, et al.
Publicado: (2022)

Small airway dysfunction in idiopathic pulmonary fibrosis
por: Yin, Chengsheng, et al.
Publicado: (2022)

Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
por: Habiel, David M., et al.
Publicado: (2014)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

A model of the aged lung epithelium in idiopathic pulmonary fibrosis
por: Shaghaghi, Hoora, et al.
Publicado: (2021)

Laryngopharyngeal pH Monitoring in Patients With Idiopathic Pulmonary Fibrosis
por: Su, Yiliang, et al.
Publicado: (2021)

Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
por: Zhang, Tingwei, et al.
Publicado: (2022)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Acute cigarette smoke exposure activates apoptotic and inflammatory programs but a second stimulus is required to induce epithelial to mesenchymal transition in COPD epithelium
por: Murray, Lynne A., et al.
Publicado: (2017)

Living with Fibrosis: From Diagnosis to Future Hope
por: Sleeman, Matthew A., et al.
Publicado: (2015)

Feasibility and Mechanism Analysis of Shenfu Injection in the Treatment of Idiopathic Pulmonary Fibrosis
por: Liu, Peipei, et al.
Publicado: (2021)

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
por: Estornut, Cristina, et al.
Publicado: (2022)

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis
por: Wang, Rui, et al.
Publicado: (2022)

The identification of metabolism-related subtypes and potential treatments for idiopathic pulmonary fibrosis
por: Yang, Changqing, et al.
Publicado: (2023)

Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis
por: Han, Meishan, et al.
Publicado: (2022)

Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution
por: Samarelli, Anna Valeria, et al.
Publicado: (2021)

Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary Fibrosis
por: Fukumoto, Jutaro, et al.
Publicado: (2022)

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
por: Guo, Hehua, et al.
Publicado: (2023)

Inflammatory pathways are upregulated in the nasal epithelium in patients with idiopathic pulmonary fibrosis
por: Sala, Marc A., et al.
Publicado: (2018)

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
por: Satsuma, Yukari, et al.
Publicado: (2020)

Idiopathic Pulmonary Fibrosis Mortality Risk Prediction Based on Artificial Intelligence: The CTPF Model
por: Wu, Xuening, et al.
Publicado: (2022)

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis
por: Kadefors, Måns, et al.
Publicado: (2022)

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Li, Hui, et al.
Publicado: (2022)

Pharmacokinetics and tissue distribution of bleomycin-induced idiopathic pulmonary fibrosis rats treated with cryptotanshinone
por: He, Xiangjun, et al.
Publicado: (2023)

Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication
por: Shen, Jiahui, et al.
Publicado: (2023)

Maimendong Decoction Improves Pulmonary Function in Rats With Idiopathic Pulmonary Fibrosis by Inhibiting Endoplasmic Reticulum Stress in AECIIs
por: Shen, Mengmeng, et al.
Publicado: (2020)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

The Idiopathic Pulmonary Fibrosis Honeycomb Cyst Contains A Mucocilary Pseudostratified Epithelium
por: Seibold, Max A., et al.
Publicado: (2013)

Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes
por: Clarke, Deborah L, et al.
Publicado: (2013)

Connective Tissue Growth Factor in Idiopathic Pulmonary Fibrosis: Breaking the Bridge
por: Effendi, Wiwin Is, et al.
Publicado: (2022)

Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2020)

The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Zhang, Wan-Tong, et al.
Publicado: (2021)

A novel gene signature based on the hub genes of COVID-19 predicts the prognosis of idiopathic pulmonary fibrosis
por: Guo, Run, et al.
Publicado: (2022)

Challenges for Clinical Drug Development in Pulmonary Fibrosis
por: White, Eric S., et al.
Publicado: (2022)

BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2022)

Investigation of the Pharmacological Effect and Mechanism of Jinbei Oral Liquid in the Treatment of Idiopathic Pulmonary Fibrosis Using Network Pharmacology and Experimental Validation
por: Zhang, Aijun, et al.
Publicado: (2022)

Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis
por: Huang, Guirui, et al.
Publicado: (2022)

Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: An exploratory, randomized, double-blinded and placebo controlled trial
por: Li, Jiansheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8bgkr2b3ngrs31k1v2faipkaq0